(Q33591791)

28 July 2017

1 reference

title

Immunosuppressive strategies in transplantation (English)

1 reference

28 July 2017

M D Denton

1

1 reference

28 July 2017

C C Magee

series ordinal

2

1 reference

28 July 2017

M H Sayegh

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

353

1 reference

28 July 2017

issue

9158

1 reference

28 July 2017

page(s)

1083-1091

1 reference

T-lymphocyte-antigen interactions in transplant rejection

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

The role of T-cell costimulatory activation pathways in transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

HLA matching in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Structure of the complex between human T-cell receptor, viral peptide and HLA-A2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Mechanisms of T cell recognition of alloantigen. The role of peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Contribution of direct and indirect recognition pathways to T cell alloreactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

The role of the CD28 receptor during T cell responses to antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

The role of CD40 in the regulation of humoral and cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Muromonab-CD3 and antithymocyte globulin in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Human renal allograft rejection: molecular characterization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

1 reference

7 January 2021

Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Long-term efficacy and safety of cyclosporine in renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Relationship between maintenance dose of cyclosporine and long-term kidney graft survival. Collaborative Transplant Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

1 reference

7 January 2021

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Tacrolimus rescue therapy for renal allograft rejection--five-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

A novel approach to the treatment of chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Anti-CD4 MoAb therapy in kidney transplantation--a pilot study in early prophylaxis of rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Transmembrane signalling via the T cell antigen receptor heterodimer and the CD2 antigen. A synergistic pathway for activation of T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Prevention and reversal of renal allograft rejection by antibody against CD45RB

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Peptide-mediated immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Decreased cytotoxic activity of natural killer cells in kidney allograft recipients treated with human HLA-derived peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Gene therapy and allotransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Transplantation tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907493-5

7 January 2021

10.1016/S0140-6736(98)07493-5

Identifiers

DOI

1 reference

28 July 2017

1 reference